Statins, hormones, and women: benefits and drawbacks for atherosclerosis and osteoporosis.
Clinical trials have shown that 3-hydoxy-3- methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, known as statins, significantly reduce the risk of both primary and secondary coronary heart disease events. Although these trials have included few women, the evidence suggests that statins are as effective in women as in men. The addition of hormone replacement therapy to statin therapy augments lowering of low- density lipoprotein cholesterol, but may not increase the favorable effects on clinical events achieved with statins alone. Finally, new data suggest that statins may also reduce the risk of osteoporotic fractures, a provocative finding still in need of verification by clinical trials.
Herrington
D M
DM
Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157-1045, USA. dherring@wfubmc.edu
Potvin Klein
K
K
D001161:Arteriosclerosis / Q000188:drug therapy / Q000517:prevention & control; D015519:Bone Density / Q000187:drug effects; D008078:Cholesterol, LDL / Q000187:drug effects; D002986:Clinical Trials as Topic; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy / Q000517:prevention & control; D011372:Progestins / Q000627:therapeutic use; D012307:Risk Factors; D016387:Women's Health
D008078:Cholesterol, LDL; D004967:Estrogens; D000960:Hypolipidemic Agents; D011372:Progestins